LIFE CHANGING BREAKTHROUGHS

Aging isn’t a mystery. It can be understood and overcome.
We are the first and largest company dedicated to the research of longevity and aging in their totality. There are no fragmented solutions to a systemic breakdown.

There are eight pathways of aging. We have established and empowered our Daughter companies to tackle them.

Learn More

focus areas

The world’s foremost longevity researchers are developing medicines in these areas.

Learn More

our companies

Each Daughter company is taking a revolutionary approach to tackling one or more of the causes of aging, with a mission of making the solutions affordable and accessible to all.

Learn More

latest news

Lua Technologies, A Subsidiary of Life Biosciences, Rated as the Leading Post-Acute Secure Messaging Solution by KLAS Research

Announcements, Company, Press Release

LUA TECHNOLOGIES, A SUBSIDIARY OF LIFE BIOSCIENCES, RATED AS THE LEADING POST-ACUTE SECURE MESSAGING SOLUTION BY KLAS RESEARCH* Top Healthcare Data and Insights Company Uses Impartial Research for Key Industry Reports Used by Providers and Payers Worldwide   BOSTON, February 14 –Lua Technologies, a subsidiary of Life Biosciences Inc, has been ranked the highest scoring post-acute secure … Continued

Read Full Article

Life Biosciences Longevity Company, Prana, Receives Orphan Designation For PBT434 For Treatment of MSA

Announcements, Company, Press Release Prana Bio

Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). This is the first time the FDA has granted orphan designation to a drug for the treatment of MSA. Orphan Drug … Continued

Read Full Article

Life Biosciences Announces Closing Of $50 Million Series B Financing Round

Announcements, Company, Press Release

BOSTON, Jan. 15, 2019 /PRNewswire/ — Life Biosciences has announced the closing of a Series B financing round of $50 million, according to Tristan Edwards, chief executive officer and co-founder. The Company initially targeted a $25 million round but upsized to meet investor demand. The proceeds of the investment will be used to continue Life Biosciences’ and its Daughter Companies’ … Continued

Read Full Article

Senolytic Therapeutics Kicks Off Q1 with High-Profile Speaking Events Featuring Co-Founders Marc Ramis and Manuel Serrano

Company, Press Release

FOR IMMEDIATE RELEASE SENOLYTIC THERAPEUTICS KICKS OFF Q1 2019 WITH HIGH-PROFILE SPEAKING EVENTS FEATURING CO-FOUNDERS MARC RAMIS AND MANUEL SERRANO  Barcelona-Based Biotech is a Daughter Company of Life Biosciences  Funded and Supported by Pioneer in the Study of Age-Related Decline   BOSTON, JANUARY 9 — Senolytic Therapeutics, an innovator in senescent cell research and one … Continued

Read Full Article

View All